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Anorexia nervosa (AN) is a life-threatening and difficult to treat mental illness with the high-
est mortality rates of any psychiatric disorder. We aimed to garner preliminary data on the
real-world use of olanzapine and aripiprazole as augmentation agents of Selective Seroto-
nin Reuptake Inhibitors (SSRIs) in adult inpatients affected by AN. We retrospectively eval-
uated the clinical charts of patients who were hospitalized between 2012 and 2014.
Patients were evaluated upon admission and discharge. We investigated eating symptom-
atology, and both general and eating psychopathology using: Hamilton Rating Scale for
Anxiety, Hamilton Rating Scale for Depression, and Yale-Brown-Cornell Eating Disorders
Scale. The charts of 75 patients were included in this study. The sample resulted equally
distributed among those receiving SSRIs and either aripiprazole or olanzapine in addition to
SSRIs. Notwithstanding a few baseline clinical differences, upon discharge all groups were
significantly improved on all measures. Interestingly, aripiprazole showed the greatest ef-
fectiveness in reducing eating-related preoccupations and rituals with a large effect size.
The body of evidence on medication management in AN is in dismal condition. Augmenta-
tion therapy is a well-established approach to a variety of mental disorders and it is often
used in every-day clinical practice with patients affected by AN as well. Nevertheless, to
date very little data is available on this topic. Results from our sample yielded promising re-
sults on the effectiveness of aripiprazole augmentation in reducing eating-related obses-
sions and compulsions. Randomized controlled trials are warranted to confirm these
encouraging findings.
Introduction
AN is a severe mental disorder with a relevant biological predisposition whose etiology is com-
plex and still largely unknown [1]. The course of AN is often relapsing and in a substantial pro-
portion of cases an enduring and treatment-resistant disorder occurs [2]. However, over the
past decades new insights into the neurobiology of this disorder emerged. In particular, several
lines of research have shed light on the imbalances of serotonin [3] and dopamine [4] systems
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in AN with the former potentially being involved in altered satiety and mood and the latter in
altered reward with respect to food and motivation [5].
No proven effective treatments, including pharmacotherapy, are currently available for pa-
tients affected by AN [6] and the difficulties in performing large-scale randomized controlled
trials (RCTs) in this research field have been widely acknowledged [7]. Earlier studies showed
that first-generation antipsychotics should be used with caution to treat AN because of short-
and long-term side effects [8]. Nevertheless, over the last years increasing interest has been de-
voted to the use of atypical antipsychotics (AAs) in the treatment of AN (for reviews see [9–
12]). The rationale for using atypical antipsychotics in AN is grounded on: a) the neurobiology
of AN, with the alterations of dopamine and serotonin pathways in the brain [3–5]; b) the anti-
dopaminergic properties of these medications that could mitigate sufferers’ obsessional think-
ing towards weight and body shape [9]; c) AA positive effects on safety, anxiety, eating
psychopathology [9] and depression [11]; d) the increase in appetite and food intake that AA
entail, consequently enhancing weight restoration, given the high-affinity profile to serotoner-
gic, histaminergic, and adrenergic receptors [9]. A handful of case reports and open trials de-
scribed the use of quetiapine [13–15], amisulpride [16], and aripiprazole [17] for adult patients
diagnosed with AN. Controlled trials investigated the effectiveness of olanzapine in adult pa-
tients with AN [18–20] providing mixed results with respect to weight gain but overall support-
ing the effectiveness of this AA on patients’ comorbid conditions like depression, anxiety, and
obsessive-compulsive traits. Nevertheless, recent meta-analysis [9,11,12] have called into ques-
tion the effectiveness of AA medications, although their usefulness for subgroups of patients
cannot be ruled out [9]. In fact, the modest number of available RCTs makes it difficult to as-
certain whether specific subgroups of patients might benefit from using AA and an individual-
ized clinical judgment should guide the treatment choice [9].
Converging evidence indicates that patients affected by AN are frequently characterized by
comorbid disorders, mainly anxiety disorders, obsessive-compulsive disorder, and major de-
pressive disorder [21,22]. Notwithstanding this overlap and some encouraging findings
[23,24], antidepressants failed to be effective in clinical trials in AN [25] and their impact on
depressive comorbidity has been recently questioned [26].
Surprisingly, evidence is still lacking as regards the combination of SSRIs and AAs. This is
noteworthy in the light of a couple of considerations. Firstly, AAs have been widely used since
decades in general psychiatry as augmentation agents for severe forms of depression and obses-
sive features [27,28]. Secondly, on one hand the association of different medications is com-
mon in clinical practice in AN [17] but on the other hand such data are very difficult to
quantify and report.
Given the aforementioned gaps in literature, with this retrospective study we aimed to gar-
ner preliminary data on the real-world use of AAs as augmentation agents of SSRIs in AN. Our
research question focused on olanzapine and aripiprazole with the former being included on
the basis of the aforementioned literature [9, 18–20]. Aripiprazole was selected in an explorato-
ry fashion because of a twofold rationale: a) its beneficial effects suggested not only by our clini-
cal experience but also by authoritative groups in the AN field [17]; b) the dearth of data on its
use in AN in spite of its efficacy on frequently reported comorbid conditions in psychiatric pa-
tients [28, 29]. We hypothesized that the augmentation of SSRIs with AAs could be more effec-
tive than SSRI monotherapy particularly with respect to depression and obsessive-compulsive
features, in line with other fields in psychiatry [28,29]. In fact, depressive symptomatology is a
frequent comorbid condition in AN, mostly for those who are hospitalized [30] as well as the
presence of obsessive traits, either eating-related or not [21,31]. Moreover, both comorbid con-
ditions can impact on patients’ engagement in treatment [32]. We expected to find olanzapine
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as more effective than other medications on weight gain [18,20], and aripiprazole and olanza-
pine as equally effective on obsessive-compulsive aspects [28] of AN.
Materials and Methods
Participants
We retrospectively evaluated the clinical charts of patients who were hospitalized between Jan-
uary 2012 and May 2014 at the ward for Eating Disorders of the San Giovanni Battista Hospital
of the University of Turin, Italy. To be included, patients had to meet full criteria for AN both
subtypes according to DSM-IV-TR [33] as assessed using the Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I) [34]. In addition, patients had to be already on an SSRI
upon admittance for at least 6 weeks and either olanzapine or aripiprazole had to be added as
augmentation therapy during hospitalization. Low-doses of benzodiazepines did not represent
an exclusion criterion.
Exclusion criteria were: a) being on different categories of antidepressants (e.g., venlafaxine,
reboxetine, trazodone, bupropione); b) lifetime use of any kind of antipsychotics or mood sta-
bilizers; c) being hospitalized primarily because of a comorbid diagnosis of psychiatric Axis I
disorders; d) use of specific pharmacotherapy because of organic comorbidities (e.g., diabetes,
epilepsy, inflammatory disorders).
According to international guidelines [35] during hospitalization all patients underwent the
same multimodal intervention. Individualized treatment plans were managed by a multidisci-
plinary team composed by psychiatrists, clinical psychologists, registered dietitians, nurses and
physicians trained in internal medicine. In more detail, the team was staffed by two psychia-
trists with substantial experience in the treatment of AN; one of them (G.A.D.) had treated pa-
tients with AN for greater than 20 years and another (N.D.) for 10 years. In addition, the
Program Director (S.F.) actively participated in clinical decision making. Given patients’ clini-
cal severity upon admittance, the management of medical instability and nutritional rehabilita-
tion had to be prioritized during the first days of treatment. After achieving medical stability,
patients were then provided with daily individual motivational and psychotherapy sessions,
and weekly psycho-educational groups to engage them as much as possible in the recovery pro-
cess. All inpatients received five structured meals during the day under a dietitian’s supervision
and enteral or parenteral feeding could be indicated as well based on clinical judgment. Blood
tests and EKG were performed as frequently as needed by patients’medical condition.
Given the retrospective design of this study, written informed consent was not required. Pa-
tients' records/information was anonymized and de-identified prior to analysis. The Ethics
Committee of the Department of Neuroscience of the University of Turin approved this study.
Measures
Patients’ height and weight were measured by a nurse at admission (T0) and discharge (T1) to
calculate Body Mass Index (BMI). At the same time points, clinical interviews were performed
by a psychiatrist to measure the weekly frequency of binge-purging behaviors (including use of
diuretics and/or laxatives) and physical exercise. The following semi-structured interviews
were also performed at both T0 and T1:
• The Hamilton Rating Scale for Anxiety (HAM-A) [36] is a clinician-administered scale of
anxiety severity. Scores range from 0 to 56 (0–7: no or minimal symptoms, 8–17: mild anxi-
ety; 18–24: moderate anxiety; and 25–30: severe anxiety). It showed good reliability, validity
and sensitivity to change [37].
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• The Hamilton Rating Scale for Depression (HAM-D) [38] is an interview with good psycho-
metric properties [39] which has to be administered by a health care professional. It assesses
depression through 21 questions. The higher the score, the more severe the depression as fol-
lows: 0–7 no depression; 8–13 mild depression; 14–18 moderate depression; 19–22 severe de-
pression; 23 very severe depression.
• The Yale-Brown-Cornell Eating Disorders Scale (YBC-EDS) [40] is a clinician-rated inter-
view with solid psychometrics that investigates core preoccupations and rituals related to eat-
ing disorders. Individual target symptoms are determined and then assessed in terms of time
occupied by symptoms, interference with functioning, distress, and degree of control over
symptoms. Four questions address preoccupations and four investigate rituals. Each item is
rated on a scale anchored at 0 (none/not present) and 4 (extreme). All eight questions are
added for the YBC-EDS total score and two YBC-EDS subtotal scores are also obtained. For
the purpose of this study (i.e., measuring obsessive-compulsive traits) the motivation sub-
scale was not included in the analysis.
Statistical analysis
The Statistical Package for Social Sciences 21.0 (SPSS, SPSS Inc., Chicago, IL) was used for all
analyses. A two-tailed alpha level of 0.05 was used for all statistical analyses.
Fisher’s exact test and one-way analysis of variance (ANOVA) with Bonferroni adjustments
for multiple comparisons were used to analyze categorical and continuous variables, respec-
tively, at baseline among the three groups.
Repeated-measures ANOVA with Bonferroni adjustments for multiple comparisons for the
between-subject analysis was then used to assess changes on all variables considered between
hospital admission and discharge.
The effect size (i.e., proportion of the variance in the dependent variable that can be ex-
plained by the independent one) of all findings was measured with the Partial Eta Squared
(ηP
2). According to Cohen’s work [41] the effect size can be assessed as small ηP
2 = 0.01–0.06;
moderate ηP
2 = 0.06–0.14; or large ηP
2>0.14.
Results
Clinical features of the sample
A total of 187 charts were overall reviewed (i.e., 100% of those admitted between January 2012
and May 2014). One-hundred and twelve had to be excluded because they failed to meet the in-
clusion criteria adopted for this study. Eighty-seven charts were discarded because of medica-
tions upon admission (39 on different antidepressants and 48 already on AAs); 19 due to a
comorbid diagnosis which required patients’ hospitalization; and 6 because of organic disor-
ders. Therefore, the charts of 75 patients were considered for this study. As shown in Table 1,
the sample was composed by adult individuals (25.20±7.62 years) affected by severe (BMI:
13.93±1.93) and frequently enduring (6.85±6.10 years) AN. Participants were mostly women
(n = 68, 90.7%).
All patients were on SSRIs (either sertraline or citalopram or escitalopram or fluoxetine)
upon admission. Given the retrospective design of this study, medications were managed per
clinical decision during the hospital stay and resulted distributed as follows: 25 individuals
(32.9%) remained on SSRIs as monotherapy (eventually increasing the dosage; SSRIs), 23
(31.6%) started aripiprazole in addition to SSRIs (ARI), and 27 (35.5%) olanzapine in addition
to SSRIs (OLA).
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The three subgroups did not differ as regards age, gender, BMI, AN subtype, duration of ill-
ness, daily hours of exercise, and abuse of diuretics; however, as shown in detail in Table 1, dif-
ferences emerged with respect to weekly binge-purging episodes and abuse of laxatives.
Mean duration of hospitalization was 34.78±9.85 days and did not differ among groups
(SSIRs 34.52±6.17; ARI 32.67±10.97; OLA 36.55±11.59, F(2,72) = 0.93, p = 0.4). Mean duration
of medication treatment was 4.96±1.62 weeks, mean olanzapine and aripiprazole doses were
6.11±3.27 and 9.13±6.33 mg/day, respectively. Occurrence of mild adverse events did not re-
quire discontinuation and was in line with previous literature [42]. The three groups did not
differ in SSRIs composition or dosage (data not shown). The SSRIs group was composed by pa-
tients receiving: sertraline (T0: 87.50±32.73 mg/day; T1: 106.25±29.12), citalopram (T0: 23.33
±5.16 mg/day; T1: 33.33±8.16), escitalopram (T0: 11±2.23 mg/day; T1:15±5), and fluoxetine
(T0: 23.33±5.16 mg/day; T1: 36.66±5.16 mg/day). For those who received SSRIs as monother-
apy, no switch to another antidepressant medication was performed. In case of increase of the
dosage, all individuals started the higher dose during the first week of inpatient treatment.
Table 1. Clinical features of the sample and baseline differences between treatment groups.
Total sample Groups of treatment Test
statistics







Women, N(%) 68(90.7) 24(96) 22(95.6) 22(81.5) 0.205
Age, years, Mean(SD) 25.43(9.4) 25.2(7.62) 26.19(11.82) 24.96(8.81) 0.887
Duration of illness, years, Mean
(SD)
6.85(6.12) 7.52(6.11) 6.29(6.92) 6.7(5.73) 0.785
AN subtype, N(%) 0.109
AN-R 50(66.7) 15(60) 13(56.5) 22(81.5)
AN-BP 25(33.3) 10(40) 10(43.5) 5(18.5)
BMI, Mean(SD) 13.93(1.93) 14.11(1.94) 14.11(2.11) 13.57(1.82) 0.5
Binging, Mean(SD) 2.21(5.61) 1.22(3.15) 4.65(8.33) 1.07(3.73) 0.041a
Purging, Mean(SD) 3.13(6.26) 3.12(5.62) 5.78(8.71) 0.77(2.81) 0.017b
Exercise, Mean(SD) 2.68(2.35) 2.52(2.32) 2.11(2.21) 3.33(2.41) 0.170
Diuretic abuse, N(%) 7(9.3) 3(12) 2(8.6) 2(7.4) 0.888
Laxative abuse, N(%) 7(9.3) 2(8) 5(21.7) 0(0) 0.020c
HAM-A 20.88(7.84) 16.12(5.22) 23.52(7.21) 23.11(8.56) 0.001d
HAM-D 23.03(7.64) 17.88(4.62) 26.48(6.73) 24.92(8.31) <0.001d
YBC-EDS T 18.82(4.38) 17.63(3.93) 18.84(5.15) 19.95(3.89) 0.170
YBC-EDS P 9.53(2.06) 8.85(1.84) 9.68(2.29) 10.06(1.95) 0.101
YBC-EDS R 9.28(2.58) 8.78(2.23) 9.16(3.07) 9.88(2.39) 0.306
Fisher’s exact test and one-way Analysis of Variance (ANOVA) with Bonferroni correction for multiple comparisons were used to analyze categorical and
numerical variables, respectively.
a significance did not hold after Bonferroni correction;
b Ola+SSRIs<Ari+SSRIs; SSRIs = Ari+SSRIs, Ola+SSRIs;
c Ari+SSRIs >Ola+SSRIs; SSRIs = Ari+SSRIs, Ola+SSRIs;
dSSRIs<Ari+SSRIs, Ola+SSRIs; Ari+SSRIs = Ola+SSRIs
Legend: SSRIs: selective serotonin reuptake inhibitors; Ari: aripiprazole; Ola: olanzapine; BMI: body mass index; AN: anorexia nervosa; AN-R: anorexia
nervosa restricting subtype; AN-BP: anorexia nervosa binge-purging subtype; Binging: weekly binging episodes; Purging: weekly purging episodes;
Exercise: weekly hours of exercise; HAM-A: Hamilton Rating Scale for Anxiety; HAM-D: Hamilton Rating Scale for Depression; YBC-EDS T: Yale-Brown-
Cornell Eating Disorders Scale—total score; YBC-EDS P: Yale-Brown-Cornell Eating Disorders Scale—preoccupation subscale; YBC-EDS R: Yale-
Brown-Cornell Eating Disorders Scale—rituals subscale.
doi:10.1371/journal.pone.0125569.t001
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Changes in clinical variables amongst groups of treatment
Considering the overall sample, significant changes with large effect sizes emerged as regards
all parameters considered (i.e., BMI, weekly binge-purging episodes and exercise, see Table 2).
As shown in Table 2, amongst the three groups no significant differences emerged with re-
spect to changes in BMI and daily hours of exercise. In contrast, ARI when compared to OLA
resulted significantly more effective in reducing purging episodes with a moderate effect size
whilst as regards binging episodes after Bonferroni correction a trend towards significance
emerged for ARI more effective than SSRIs (p = 0.09) and OLA (p = 0.057).
Changes in general and eating psychopathology amongst groups of
treatment
Considering the sample as a whole, significant changes with large effect sizes emerged on all
semi-structured interviews considered (i.e., HAM-A, HAM-D, YBC-EDS total score and both
subscales) comparing T0 and T1 scores.
As shown in Table 3, at the two time-points considered the three groups did not differ signifi-
cantly from one another as regards anxiety (i.e., HAM-A). In contrast, differences on depression
(i.e., HAM-D) and eating-related rituals and preoccupations (i.e., YBC-EDS total score and both
preoccupations and rituals subscales) emerged. As shown in Table 3, OLA showed a trend to-
wards a greater effect than SSRIs on depression. With respect to eating preoccupations and
Table 2. Changes in clinical variables between admission (T0) and discharge (T1) amongst groups of treatment.
Total SSRIs Ari + SSRIs Ola + SSRIs Test statistics
(n = 75,100%) (n = 25,32.9%) (n = 23,31.6%) (n = 27,35.5%)
Main effect of time Main effect of group Group-by-time
interaction










BMI 57.47 <0.001 0.44 0.63 0.533 0.02 0.27 0.763 0.007
T0 13.93(1.93) 14.11(1.94) 14.15(2.12) 13.57(1.81)
T1 15.01(1.63) 15.06(1.47) 15.21(1.91) 14.77(1.55)
Binging 13.04 0.001 0.15 3.49 0.036a 0.09 2.63 0.079 0.07
T0 2.21(5.61) 1.22(3.15) 4.65(8.33) 1.13(3.73)
T1 0.41(1.83) 0.21(0.41) 1.04(3.22) 0.04(0.19)
Purging 17.95 <0.001 0.2 3.63 0.032b 0.09 3.95 0.024 0.1
T0 3.11(6.26) 3.12(5.62) 5.78(8.61) 0.78(2.82)
T1 0.61(2.69) 0.92(2.37) 0.87(4.17) 0.07(0.38)
Exercise 85.88 <0.001 0.54 2.19 0.12 0.06 3.48 0.036 0.09
T0 2.68(2.35) 2.52(2.32) 2.12(2.21) 3.33(2.41)
T1 0.71(0.93) 1.22(1.15) 0.21(0.42) 0.68(0.82)
Repeated-measures analysis of variance (ANOVA) with Bonferroni adjustments for multiple comparisons was conducted.
a Ari+SSRIs>Ola+SSRIs (trend towards significance after Bonferroni correction, p = 0.057); Ari+SSRIs >SSRIs (trend towards significance after
Bonferroni correction, p = 0.09); SSRIs = Ola+SSRIs;
b Ari+SSRIs >Ola+SSRIs; SSRIs = Ari+SSRIs, Ola+SSRIs.
Legend: SSRIs: selective serotonin reuptake inhibitors; Ari: aripiprazole; Ola: olanzapine; BMI: body mass index; Binging: weekly binging episodes;
Purging: weekly purging episodes; Exercise: weekly hours of exercise.
ηP
2 = Partial Eta Squared; Cohen’s effect size: 0.01–0.06 = small effect; 0.06–0.14 = moderate effect; >0.14 = large effect.
doi:10.1371/journal.pone.0125569.t002
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rituals, ARI reported a significantly greater improvement with a large effect size on the global
score and both subscales of the YBC-EDS when compared to both other groups (Fig 1).
Discussion
Nomedications are currently indicated for the treatment of AN [6]. With this study we aimed to
garner preliminary real-world data on the management of the combined use of pharmacological
agents in AN with the overarching aim to stimulate the debate on this topic. All in all, we found
encouraging data on the use of aripiprazole as augmentation agent to reduce eating-related pre-
occupations and rituals although caution is needed when interpreting these findings.
In fact, it should be borne in mind that those patients who were started with an augmenta-
tion agent were characterized on average by greater clinical severity upon admission than those
who received SSRIs as monotherapy, as expected according to the retrospective design of this
study. Still, in order to make the sample as clean as possible, many patients (n = 112) had to be
excluded according to the aforementioned criteria. Taken together, these elements may
Table 3. Changes in anxiety, depression, social anxiety and eating preoccupations/rituals as measured with semi-structured interviews between
admission (T0) and discharge (T1) amongst groups of treatment.
Total SSRIs Ari + SSRIs Ola + SSRIs Test statistics
(n = 75,100%) (n = 25,32.9%) (n = 23,31.6%) (n = 27,35.5%)
Main effect of time Main effect of group Group-by-time
interaction










HAM-A 52.89 <0.001 0.42 2.95 0.059 0.77 11.38 <0.001 0.24
T0 20.87(7.84) 16.12(5.22) 23.52(7.21) 23.11(8.56)
T1 13.43(7.04) 14.92(4.88) 10(6.16) 15.04(8.52)
HAM-D 66.09 <0.001 0.48 3.15 0.049a 0.08 10.77 <0.001 0.23
T0 23.03(7.64) 17.88(4.61) 26.48(6.73) 24.92(8.31)
T1 14.36(6.43) 15.82(4.26) 12.17(7.63) 14.92(6.74)
YBC-EDS
T
86.01 <0.001 0.55 5.39 0.007b 0.13 15.96 <0.001 0.31
T0 18.82(4.38) 17.63(3.93) 18.84(5.15) 19.95(3.89)
T1 13.06(5.93) 16.29(3.76) 8.64(4.63) 13.87(6.42)
YBC-EDS
P
80.63 <0.001 0.53 5.75 0.005b 0.14 19.41 <0.001 0.35
T0 9.53(2.06) 8.85(1.84) 9.68(2.29) 10.06(1.95)
T1 6.73(3.06) 8.48(2.01) 4.38(2.35) 7.14(3.22)
YBC-EDS
R
75.97 <0.001 0.52 4.32 0.017b 0.11 10.63 <0.001 0.23
T0 9.28(2.58) 8.78(2.23) 9.16(3.07) 9.88(2.39)
T1 6.33(2.99) 7.81(2.01) 4.26(2.41) 6.73(3.31)
Repeated-measures analysis of variance (ANOVA) with Bonferroni adjustments for multiple comparisons was conducted.
a Ola+SSRIs >SSRIs (trend towards significance after Bonferroni correction, p = 0.057); SSRIs = Ari+SSRIs; Ari+SSRIs = Ola+SSRIs.
b Ari+SSRIs >SSRIs, Ola+SSRIs; SSRIs = Ola+SSRIs.
Legend: SSRIs: selective serotonin reuptake inhibitors; Ari: aripiprazole; Ola: olanzapine; HAM-A: Hamilton Rating Scale for Anxiety; HAM-D: Hamilton
Rating Scale for Depression; YBC-EDS T: Yale-Brown-Cornell Eating Disorders Scale—total score; YBC-EDS P: Yale-Brown-Cornell Eating Disorders
Scale—preoccupation subscale; YBC-EDS R: Yale-Brown-Cornell Eating Disorders Scale—rituals subscale.
ηP
2 = Partial Eta Squared; Cohen’s effect size: 0.01–0.06 = small effect; 0.06–0.14 = moderate effect; >0.14 = large effect.
doi:10.1371/journal.pone.0125569.t003
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represent a selection bias. This said, we believe these data could represent a useful, although
preliminary, insight into a neglected topic, namely the use of AAs as augmentation agents in
AN. Still, in line with the exploratory aim of this work, to the best of the authors’ knowledge,
only very little data [17,43] is currently available on the use of aripiprazole in AN.
Fig 1. Changes in Yale-Brown-Cornell Eating Disorders Scale (YBC-EDS) total score (1a) and
preoccupations (1b) and rituals (1c) subscales amongst groups of treatment at admission (T0) and
discharge (T1). All groups significantly improved on all YBC-EDS scales but those patients undergoing
aripiprazole in combination with Selective Serotonin Reuptake Inhibitors (SSRIs) reported a significantly
larger improvement when compared to the other groups. Mean scores and 95% confidence intervals are
shown as columns and bars, respectively.
doi:10.1371/journal.pone.0125569.g001
Atypical Antipsychotics in Anorexia Nervosa
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The relevance of clinical judgment has been also recently highlighted [9] and in this study,
per clinical decision, those with a greater number of weekly binge-purging episodes were found
to have been started with aripiprazole. This choice was made by our group in light of the hun-
ger-neutrality of this medication; therefore, it was most often used in order to avoid exacerbat-
ing binge-purging behaviors. In contrast, those with severe physical hyperactivity were started
with olanzapine because of its beneficial effects on anxiety, agitation, and aggressiveness also
due to its sedative properties [8,19]. Given the greater number of weekly binge-purging epi-
sodes in the ARI group when compared to OLA, it is unwise to draw firm conclusions on the
effectiveness of aripiprazole in reducing binge-purging episodes. Although intriguing, future
studies on a more homogeneous sample are warranted to shed light on this issue.
Differently from what initially hypothesized, BMI significantly increased at discharge with
no differences amongst groups. Although olanzapine-induced weight gain in AN has been
questioned [11,12,19], such a compound has been found to play a role in this regard [20]. How-
ever, since the three groups had comparable BMI upon admittance, the lack of differences
amongst groups is of interest and highlights the role of the multimodal approach adopted dur-
ing hospitalization instead of the relevance of medications per se.
The main finding of this work is represented by the positive effects with large effect size we
found with the adjunct of aripiprazole to antidepressants on eating-related obsessive-compul-
sive symptomatology. Notwithstanding comparable baseline scores, the ARI group showed a
significantly more marked improvement on YBC-EDS global score and both subscales when
compared to the others. Obsessive-compulsive traits are frequently intertwined with AN since
they not only characterize the course of illness but also tend to predate its onset [31]. Still, the
lifetime prevalence of OCD is elevated in AN [21]. Moreover, this improvement is of interest
since it has been found that obsessive-compulsive traits adversely affect outcome [44] and it is
in line with what Trunko and collaborators [17] described in their case report. In fact, the latter
group described how aripiprazole contributed to improve several psychopathological aspects of
AN (e.g., distress around eating, food and weight-related obsessional thoughts) and comorbid
conditions like depression and generalized anxiety [17]. Another interesting element is that ob-
sessions have been recently related to purging behaviors [45] in AN and we consistently found
aripiprazole as effective on both aspects.
Speculating on the potential mechanisms by which this medication might be effective is way
beyond the scope of this paper. Nevertheless, it could be raised the hypothesis that its partial
agonist action might be of some utility in modulating dopamine levels which are strictly related
to anxiety in AN [4]. Also, it is not even possible to ascertain whether such an improvement is
related to anxious/depressive comorbidity or to the effect of aripiprazole itself. Finally, patients
with psychotic symptoms [46] or at least AN-related delusional aspects might have benefited
from the antipsychotic properties of aripiprazole. In fact, it is noteworthy that psychotic fea-
tures occur in 1 out 5 cases of AN with delusional thinking correlating with drive-for-thinness
but not with other indexes of illness severity, including BMI [47]. Given the potential clinical
implications of this finding, further studies may want to better investigate such
encouraging data.
With respect to general psychopathology, both augmentation agents did not result as more
effective than SSRIs alone in reducing anxiety; olanzapine showed only a trend towards a more
beneficial result on depression when compared to SSRIs. Again, the SSRIs group was signifi-
cantly less anxious and depressed than ARI and OLA. Therefore, the use of AAs could be in
line with treatment principles that are applied to other psychiatry disorders (e.g., severe depres-
sion and obsessive-compulsive disorders). In such cases, augmentation with AAs is a therapeu-
tic option in case of scarce or only partial response to SSRIs and it may be of some help with
comorbid conditions in AN as well. On the contrary, specific effects failed to emerge in this
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sample and our hypothesis was not confirmed in this regard although baseline differences
should be borne in mind when interpreting these results. Still, our findings are only partially in
line with previous studies reporting olanzapine to be effective on depression and anxiety
[10,19,48]. Nevertheless, previous work focused on outpatients and olanzapine was not used as
an augmentation agent; this is of importance since SSRIs could modify the antidepressant effect
of olanzapine in monotherapy. On the other hand, the dearth of clinical studies on aripiprazole
makes it difficult to compare our data with the current literature.
Some limitations should be acknowledged. First, a retrospective design was adopted and the
groups were not randomized; as a result, clinical severity was not homogeneous across groups.
Relatedly, some differences with respect to eating symptomatology emerged. Still, no self-re-
port instruments were adopted and both time and dose were flexible. Moreover, length of treat-
ment may impact medication effects; namely, the effects of AAs could be overestimated given
their more rapid action when compared to SSRIs. Finally, olanzapine and aripiprazole were
slightly unmatched as regards equivalent doses; however, the latter were established according
to the literature on the spectrum of psychotic disorders [49] so differences may exist for AN.
In closing, we found aripiprazole to be mostly effective in reducing eating psychopathology,
namely eating-related preoccupations and rituals, on a sample of inpatients diagnosed with
AN. Aripiprazole did not differ instead from either SSRIs as stand-alone therapy or olanzapine
as augmentation agent of SSRIs in either weight gain or improvement of eating symptomatolo-
gy and general psychopathology. Future double blind randomized controlled trials are war-
ranted to confirm these novel and promising preliminary data on the use of augmentation
strategies in AN. Moreover, as recently proposed [9], research should also endeavor to identify
what subgroups of patients could benefit more from AA augmentation.
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